ClinicalTrials.gg
CompletedNCT04029090Updated Jul 15, 2026Results posted

A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjects

A Phase 1 interventional study of MCI-186 and MCI-186 in Healthy Adult Subjects, sponsored by Shionogi. Completed at 1 site in Japan. Open to male participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Shionogi · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Sep 2018, registered Jul 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
20 Years to 55 Years
Sex
Male
01

Study summary

To evaluate the effect of MCI-186 on the QT interval corrected for heart rate using Fridericia's formula (QTcF)

02

Conditions studied

  • Healthy Adult Subjects
03

In context

Lead sponsor

Shionogi is the lead sponsor of 105 studies on the registry; 10 are open to participants now.

Of its 39 completed or terminated interventional studies of FDA-regulated products, 21 (54%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males aged 20 to 55 years (both inclusive) at signature of the Form (ICF).
  • Able to provide written informed consent to participate in this study after reading the ICF, and after having the opportunity to discuss the study with the Investigator or designee, before any screening or study related procedures take place.
  • In the Investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements.
  • A body weight of ≥45 kg and a (BMI) ranging from 18 to 30 kg/m2 (both inclusive) at screening and Day -1.
  • Good health and free from illness or disease in the opinion of the investigator on the basis of a physical examination, medical history, , vital sign, and clinical laboratory test (biochemistry, hematology, coagulation and urinalysis) at screening and Day -1.
  • Male subjects must practice effective during the study, from the time of the first dose of Medicinal Product (IMP) until 14 days after the last dose of IMP.

Exclusion criteria

Exclusion Criteria:

  • Subjects with PR >240 msec, QRS ≥120 msec, or >450 msec on the screening or Day -1 , or any electrocardiographic abnormality in the opinion of the Investigator.
  • Subject who has a history of cardiac disease or arrhythmias that can cause QTc prolongation.
  • Subject who has a family history of Torsade de Pointes, long-QT syndrome, hypokalemia or sudden death.
  • Subjects with potassium levels outside of the laboratory reference ranges at screening or Day -1.
  • Subjects with clinically significant deviations from normal in physical examination, vital signs, ECG or clinical laboratory test at screening or Day -1 in the opinion of the Investigator.
  • Presence or history of any clinically significant disease or organ dysfunction in the opinion of the Investigator.
  • Presence or history of allergy to food, any medical product or relevant that is of clinical significant.
  • Subjects were previously administered MCI-186.
  • Presence or history of alcohol abuse or a positive alcohol test.
  • Presence or history of drug abuse or a positive drug screen test.
  • Positive test for virus antibody, surface antigen, (HIV) antigen/antibody or syphilis test at screening.
  • Participation in another trial within 12 weeks or 5 times the half-life of the drug whichever is longer before providing a signed ICF. For biologics, the minimum period is at least 24 weeks or the period of the pharmacodynamic effect, or 10 times the half-life of the drug, whichever is longer before providing a signed ICF.
  • Donate blood more than 200 mL within 4 weeks, 400 mL within 12 weeks or 1000 mL within 52 weeks, respectively before providing a signed ICF.
  • Donate plasma or component within 2 weeks before providing a signed ICF.
  • Use of any prescription or non-prescription medications including herbal remedies and vitamin/mineral/protein supplements, except for acetylsalicylic acid, within 7 days prior to IMPs dosing.
  • Use of tobacco or nicotine containing products for 24 hours before each visit of screening or Day -1.
  • Consumption of alcohol, xanthines, or grapefruit containing products for 24 hours before each visit of screening or Day -1.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Sequence 1

    Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment A, then Treatment C, then Treatment B (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)

    Drug: MCI-186 · Drug: Placebo

  • Experimental
    Sequence 2

    Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment B, then Treatment A, then Treatment C (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)

    Drug: MCI-186 · Drug: Placebo

  • Experimental
    Sequence 3

    Subjects will receive a single intravenous dose of MCI-186 as a 1-hour infusion in the treatment sequence: first Treatment C, then Treatment B, then Treatment A (Treatment A= 60 mg of MCI-186, Treatment B= 300 mg of MCI-186, treatment C=0.9% w/v saline)

    Drug: MCI-186 · Drug: Placebo

Interventions

  • A single dose of 60 mg MCI-186 over 60 min will be intravenously administered.

    Also known as: Edaravone

  • A single dose of 300 mg MCI-186 over 60 min will be intravenously administered.

    Also known as: Edaravone

  • DrugPlacebo

    A single dose of 0.9% w/v saline over 60 min will be intravenously administered.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in QTcF(ΔQTcF) With Placebo Adjustment (ΔΔQTcF) at Cmax of MCI-186

    The primary outcome endpoint was based on an analysis of the regression relationship between ΔQTcF and the concentration of MCI-186 at matching times post-dose, including adjustment for placebo treatments.

    Time frame: 45 min pre-dose to 24 h post-dose

Secondary outcomes

  1. Change From Baseline of Heart Rate(HR) by Timepoint

    Time frame: Pre-dose to 24h post-dose

  2. Change From Baseline of PR Interval by Timepoint

    Time frame: Pre-dose to 24h post-dose

  3. Change From Baseline of QRS Interval by Timepoint

    Time frame: Pre-dose to 24h post-dose

  4. Change From Baseline of QTcF by Timepoint

    Time frame: Pre-dose to 24h post-dose

  5. Plasma Concentration of MCI-186

    Time frame: Pre-dose to 24h post-dose

  6. Pharmacokinetic(PK) Parameters - Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC 0-inf) of MCI-186

    Time frame: Pre-dose to 24h post-dose

  7. PK Parameters - Maximum Plasma Concentration (Cmax) of MCI-186

    Time frame: Pre-dose to 24h post-dose

  8. Number of Participants With Adverse Events (AEs)

    Time frame: Day 1 to 9

07

Results

Posted Nov 21, 2024

Participant flow

Participant flow — Overall Study
MilestoneSequence 1 (Treatment A, Then Treatment C, Then Treatment B)Sequence 2 (Treatment B, Then Treatment A, Then Treatment C)Sequence 3 (Treatment C, Then Treatment B, Then Treatment A)
Started999
Completed889
Not completed110
Withdrew: Protocol violation100
Withdrew: Withdrawal by subject010

Outcome measures

PrimaryChange From Baseline in QTcF(ΔQTcF) With Placebo Adjustment (ΔΔQTcF) at Cmax of MCI-186

The primary outcome endpoint was based on an analysis of the regression relationship between ΔQTcF and the concentration of MCI-186 at matching times post-dose, including adjustment for placebo treatments.

Time frame:
45 min pre-dose to 24 h post-dose
Reported as:
Mean · ms
Change From Baseline in QTcF(ΔQTcF) With Placebo Adjustment (ΔΔQTcF) at Cmax of MCI-186
msMCI-186 60mgMCI-186 300mg
Change From Baseline in QTcF(ΔQTcF) With Placebo Adjustment (ΔΔQTcF) at Cmax of MCI-186-0.5 (-1.5 to 0.5)0.5 (-1.0 to 1.9)
SecondaryChange From Baseline of Heart Rate(HR) by Timepoint
Time frame:
Pre-dose to 24h post-dose
Reported as:
Mean · beats per minute
Change From Baseline of Heart Rate(HR) by Timepoint
beats per minuteMCI-186 60mgMCI-186 300mgPlacebo
30min0.2 ± 2.90-0.2 ± 2.470.1 ± 2.59
60min0.6 ± 3.211 ± 3.080.8 ± 3.02
75min1 ± 3.431.1 ± 3.141.1 ± 3.26
90min0.4 ± 3.171.8 ± 3.631.6 ± 3.81
105min0.6 ± 3.273.1 ± 3.551.8 ± 3.91
2hr1.7 ± 3.563.4 ± 3.243.4 ± 3.8
3hr1.8 ± 4.014 ± 3.692.6 ± 3.44
4hr2.1 ± 4.283.8 ± 4.223.1 ± 4.57
6hr7.6 ± 4.699.3 ± 5.189.1 ± 4.13
8hr8.1 ± 5.4410.2 ± 6.2610.3 ± 7.34
12hr7.1 ± 4.89.1 ± 6.777.4 ± 5.83
24hr1.1 ± 4.524.6 ± 6.92.7 ± 4.01
SecondaryChange From Baseline of PR Interval by Timepoint
Time frame:
Pre-dose to 24h post-dose
Reported as:
Mean · msec
Change From Baseline of PR Interval by Timepoint
msecMCI-186 60mgMCI-186 300mgPlacebo
30min-0.4 ± 3.720 ± 6.14-1 ± 6.29
60min-2.1 ± 3.74-0.3 ± 6.79-1.4 ± 5.93
75min-2.2 ± 4.43-1.8 ± 5.53-2.5 ± 4.68
90min-2.3 ± 4.29-2.4 ± 6.81-2.8 ± 4.91
105min-1.1 ± 4.17-2.2 ± 7.91-3.1 ± 5.51
2hr-2.8 ± 4.51-3.2 ± 7.96-2.3 ± 7.2
3hr-4 ± 6.05-5.1 ± 7.34-1.7 ± 6.46
4hr-4.6 ± 5.81-6.4 ± 7.6-3.4 ± 5.99
6hr-4.2 ± 5.99-5.9 ± 8.36-5.3 ± 8.64
8hr-7.3 ± 6.01-7.8 ± 8.58-7.9 ± 7.49
12h-2.4 ± 7.96-5.5 ± 10.72-3.5 ± 9.46
24hr1.4 ± 6.87-1 ± 7.73-0.6 ± 7.16
SecondaryChange From Baseline of QRS Interval by Timepoint
Time frame:
Pre-dose to 24h post-dose
Reported as:
Mean · msec
Change From Baseline of QRS Interval by Timepoint
msecMCI-186 60mgMCI-186 300mgPlacebo
30min3.4 ± 5.033.4 ± 3.533.4 ± 3.65
60min4.7 ± 3.545 ± 5.234.1 ± 3.95
75min4.1 ± 5.024.1 ± 3.863.6 ± 3.98
90min3.5 ± 3.613.5 ± 4.43.2 ± 4.13
105min3.2 ± 3.943.2 ± 3.642.9 ± 4.45
2hr1.4 ± 3.352.1 ± 4.621.9 ± 3.85
3hr0.2 ± 4.57-0.4 ± 4.470.1 ± 5.56
4hr0.7 ± 5.47-0.6 ± 6.061.4 ± 5.56
6hr-7.3 ± 7.31-5.8 ± 7.42-4.8 ± 6.48
8hr-6.4 ± 7.39-6.4 ± 6.63-5.5 ± 7.9
12hr-6.4 ± 6.26-7 ± 7.86-4.2 ± 7.99
24hr-6 ± 4.15-8 ± 5.13-5.6 ± 5.06
SecondaryChange From Baseline of QTcF by Timepoint
Time frame:
Pre-dose to 24h post-dose
Reported as:
Mean · msec
Change From Baseline of QTcF by Timepoint
msecMCI-186 60mgMCI-186 300mgPlacebo
30min0.7 ± 1.91-1.8 ± 5.060.2 ± 1.94
60min0.2 ± 1.87-0.7 ± 3.62-0.1 ± 1.95
75min-0.6 ± 1.83-1.1 ± 3.59-0.7 ± 2.92
90min0.1 ± 2.53-1.3 ± 4.15-0.9 ± 3.24
105min-0.3 ± 2.7-1.3 ± 3.41-0.8 ± 2.53
2hr-0.4 ± 3.28-2.1 ± 6.03-1.5 ± 3.31
3hr0.3 ± 3.27-2 ± 5.31-0.4 ± 2.42
4hr0.4 ± 3.08-2 ± 5.46-1 ± 2.38
6hr1.5 ± 3.173.5 ± 6.972.1 ± 4.05
8hr0.6 ± 3.390.3 ± 5.160.9 ± 5.32
12hr0.5 ± 3.990.4 ± 4.140.9 ± 3.33
24hr0 ± 3.82-0.7 ± 5.56-0.2 ± 2.9
SecondaryPlasma Concentration of MCI-186
Time frame:
Pre-dose to 24h post-dose
Reported as:
Mean · ng/mL
Plasma Concentration of MCI-186
ng/mLMCI-186 60mgMCI-186 300mg
30min1039 ± 140.07393 ± 1770
60min791.3 ± 147.07412 ± 1968
75min454.4 ± 101.64864 ± 1606
90min308.3 ± 71.223522 ± 1235
105min227.6 ± 54.482578 ± 932.7
2hr176.1 ± 43.851990 ± 733.5
3hr83.60 ± 23.66874.5 ± 326.8
4hr51.28 ± 15.49512.7 ± 197.6
6hr20.39 ± 7.148166.3 ± 69.70
8hr12.34 ± 4.68989.91 ± 39.59
12hr6.522 ± 2.65237.48 ± 16.83
24hr2.684 ± 1.54710.65 ± 4.026
SecondaryPharmacokinetic(PK) Parameters - Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC 0-inf) of MCI-186
Time frame:
Pre-dose to 24h post-dose
Reported as:
Geometric mean · ng·h/mL
Pharmacokinetic(PK) Parameters - Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC 0-inf) of MCI-186
ng·h/mLMCI-186 60mgMCI-186 300mg
Pharmacokinetic(PK) Parameters - Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC 0-inf) of MCI-1861549.22 ± 20.512916.94 ± 33.3
SecondaryPK Parameters - Maximum Plasma Concentration (Cmax) of MCI-186
Time frame:
Pre-dose to 24h post-dose
Reported as:
Geometric mean · ng/mL
PK Parameters - Maximum Plasma Concentration (Cmax) of MCI-186
ng/mLMCI-186 60mgMCI-186 300mg
PK Parameters - Maximum Plasma Concentration (Cmax) of MCI-1861030 ± 14.17566 ± 25.1
SecondaryNumber of Participants With Adverse Events (AEs)
Time frame:
Day 1 to 9
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsMCI-186 60mgMCI-186 300mgPlacebo
Number of Participants With Adverse Events (AEs)111

Adverse events

Collected over up to 9 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MCI-186 60mg0/27 (0%)0/27 (0%)1/27 (3.7%)
MCI-186 300mg0/26 (0%)0/26 (0%)1/26 (3.8%)
Placebo0/25 (0%)0/25 (0%)1/25 (4%)
Most frequent other events
Most frequent other events
EventMCI-186 60mgMCI-186 300mgPlacebo
HeadacheNervous system disorders0/270/261/25
GastroenteritisInfections and infestations0/271/260/25
PharyngitisInfections and infestations1/270/260/25

Baseline characteristics

Age, Continuous
Age, Continuous(years)Sequence 1 (Treatment A, Then Treatment C, Then Treatment B)Sequence 2 (Treatment B, Then Treatment A, Then Treatment C)Sequence 3 (Treatment C, Then Treatment B, Then Treatment A)Total
Mean29.3 ± 9.828.7 ± 10.633.6 ± 9.830.5 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1 (Treatment A, Then Treatment C, Then Treatment B)Sequence 2 (Treatment B, Then Treatment A, Then Treatment C)Sequence 3 (Treatment C, Then Treatment B, Then Treatment A)Total
Female0000
Male99927
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1 (Treatment A, Then Treatment C, Then Treatment B)Sequence 2 (Treatment B, Then Treatment A, Then Treatment C)Sequence 3 (Treatment C, Then Treatment B, Then Treatment A)Total
American Indian or Alaska Native0000
Asian99927
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

1 site
  • Investigational site
    Tokyo, Japan
09

References and documents

Publications

  • Shimizu H, Inoue S, Endo M, Nakamaru Y, Yoshida K, Natori T, Kakubari M, Akimoto M, Kondo K. A Randomized, Single-Blind, Placebo-Controlled, 3-Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects. Clin Pharmacol Drug Dev. 2021 Jan;10(1):46-56. doi: 10.1002/cpdd.814. Epub 2020 Jun 15. PubMed 32543120 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Oct 2018, 1 month.

Results were first posted in Nov 2024, 6 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2019
First posted
Jul 23, 2019
StartActual
Sep 18, 2018
Primary completionActual
Oct 20, 2018
CompletionActual
Oct 23, 2018
Results first posted
Nov 21, 2024
Last update
Jul 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04029090
Lead sponsor
Shionogi
Responsible party
Sponsor
First posted
Jul 23, 2019
Start date
Sep 18, 2018
Primary completion
Oct 20, 2018
Completion
Oct 23, 2018
Results posted
Nov 21, 2024
Last update
Jul 15, 2026

Study contacts

Shionogi Clinical Trials Administrator Clinical Support Help Line
study director · Shionogi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Edaravone

Start the discussion